CytomX Therapeutics Stock Forecast, Price & News

CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions

Is CytomX Therapeutics a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CytomX Therapeutics stock.
View analyst ratings for CytomX Therapeutics or view top-rated stocks.

How has CytomX Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

CytomX Therapeutics' stock was trading at $5.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CTMX shares have decreased by 0.9% and is now trading at $5.82.
View which stocks have been most impacted by COVID-19.

When is CytomX Therapeutics' next earnings date?

CytomX Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for CytomX Therapeutics.

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) released its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.05. CytomX Therapeutics had a negative trailing twelve-month return on equity of 65.76% and a negative net margin of 108.85%. During the same period in the prior year, the business earned ($0.32) EPS.
View CytomX Therapeutics' earnings history.

What price target have analysts set for CTMX?

6 Wall Street analysts have issued 12-month target prices for CytomX Therapeutics' stock. Their forecasts range from $7.00 to $16.00. On average, they expect CytomX Therapeutics' stock price to reach $13.00 in the next year. This suggests a possible upside of 123.4% from the stock's current price.
View analysts' price targets for CytomX Therapeutics or view top-rated stocks among Wall Street analysts.

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the following people:

• Sean A. McCarthy, Chairman, President & Chief Executive Officer (LinkedIn Profile)
• Carlos E. Campoy, Chief Financial Officer & Senior Vice President
• Marcia P. Belvin, Senior Vice President & Head-Research
• Alison L. Hannah, Chief Medical Officer & Senior Vice President
• Amy C. Peterson, Chief Development Officer & Executive VP

What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO?

11 employees have rated CytomX Therapeutics CEO Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among CytomX Therapeutics' employees.

Who are some of CytomX Therapeutics' key competitors?

Some companies that are related to CytomX Therapeutics include Myovant Sciences (MYOV), ADC Therapeutics (ADCT), Amarin (AMRN), ImmunoGen (IMGN), NGM Biopharmaceuticals (NGM), FibroGen (FGEN), Madrigal Pharmaceuticals (MDGL), Xenon Pharmaceuticals (XENE), Organogenesis (ORGO), uniQure (QURE), MorphoSys (MOR), ALX Oncology (ALXO), Axsome Therapeutics (AXSM), Nurix Therapeutics (NRIX) and Amneal Pharmaceuticals (AMRX).
View all of CTMX's competitors.

What other stocks do shareholders of CytomX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (9.66%), BlackRock Inc. (7.74%), Candriam Luxembourg S.C.A. (5.07%), Victory Capital Management Inc. (5.02%), Great Point Partners LLC (2.30%) and Altium Capital Management LP (1.89%).
View institutional ownership trends for CytomX Therapeutics.

Which institutional investors are selling CytomX Therapeutics stock?

CTMX stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, Morgan Stanley, Assenagon Asset Management S.A., Dimensional Fund Advisors LP, Citigroup Inc., Two Sigma Advisers LP, Renaissance Technologies LLC, and Point72 Asset Management L.P..
View insider buying and selling activity for CytomX Therapeutics or view top insider-selling stocks.

Which institutional investors are buying CytomX Therapeutics stock?

CTMX stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Great Point Partners LLC, Victory Capital Management Inc., Altium Capital Management LP, Millennium Management LLC, GSA Capital Partners LLP, AXA S.A., and Goldman Sachs Group Inc..
View insider buying and selling activity for CytomX Therapeutics or or view top insider-buying stocks.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $5.82.

How much money does CytomX Therapeutics make?

CytomX Therapeutics has a market capitalization of $379.75 million and generates $100.36 million in revenue each year. The biotechnology company earns $-32.88 million in net income (profit) each year or ($1.22) on an earnings per share basis.

How many employees does CytomX Therapeutics have?

CytomX Therapeutics employs 145 workers across the globe.

What is CytomX Therapeutics' official website?

The official website for CytomX Therapeutics is www.cytomx.com.

Where are CytomX Therapeutics' headquarters?

CytomX Therapeutics is headquartered at 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (605) 515-3185, via email at [email protected], or via fax at 650-351-0353.